MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
MADRIGAL PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$447.09−2.65 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $13.03B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$8.19 (+1.87%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
MADRIGAL PHARMACEUTICALS, INC. grew revenue 149.0% to $1.28B over the twelve months to Jun 30, 2026. Free cash flow was -$206.29M.
Revenue
$1.28B
+149.0% vs. a year earlier
Operating income
-$322.62M
TTM Q2 2026
Free cash flow
-$206.29M
TTM Q2 2026
EPS, diluted
-$11.28
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $13.03B
- P/E ratio
- –
- Price to sales
- 10.15
- Price to book
- 24.88
- Dividend yield
- –
- Free cash flow yield
- -1.58%
Fundamentals
- Revenue
- $1.28B
- Net income
- -$325.10M
- EPS, diluted
- -$11.28
- Free cash flow
- -$206.29M
- Book value per share
- $17.97
- Diluted shares
- 29M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$1.28B+149.0% YoY
Gross profit
–
Operating income
-$322.62M
Net income
-$325.10M
EPS, diluted
-$11.28
Free cash flow
-$206.29M
Reported periodTrailing twelve months